Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target

Researchers led by Richard DiMarchi and Matthias Tschöp say an experimental GIP/glucagon drug may deliver weight loss comparable to GLP-1-based treatments at high doses, potentially with less nausea and vomiting. The findings are based on rodent and monkey studies and remain unproven in humans, but they could challenge the current GLP-1-centered obesity drug paradigm. BlueWater Biosciences funded the work, which was published in Molecular Metabolism.

Analysis

The real market implication is not that GLP-1 is obsolete, but that the obesity franchise is moving from a single-mechanism story to a multi-parameter optimization problem: efficacy, tolerability, and manufacturability. If a GLP-1-free combo can deliver similar weight loss with fewer GI side effects, the value shifts away from simple receptor branding and toward whoever can best industrialize peptide design, dosing convenience, and payer-friendly persistence. That is a direct threat to premium multiple assumptions embedded in the entire incretin stack, especially for assets whose differentiation is primarily “more weight loss” rather than better retention.

Second-order winners are likely to be platform players and enablers rather than one specific drugmaker. Companies with deep discovery engines, peptide chemistry, and formulation know-how should gain bargaining power because the market will increasingly pay for optionality across several obesity mechanisms instead of a single winner-take-all pathway. By contrast, pure-play obesity names with near-term launches face a higher bar: even a credible preclinical alternative can compress forward expectations if it raises the chance that today’s regimen becomes tomorrow’s bridge therapy rather than the endpoint.

The key risk is timing mismatch. Animal data can reset sentiment quickly, but actual human read-through is probably a 12-24 month event, so the near-term move is more about multiple compression than revenue displacement. A major reversal would require either failed translation in phase 1/2 or superior real-world adherence on existing GLP-1s, which would keep prescribers anchored to the known class despite side effects. The contrarian take is that tolerability may matter less than headline efficacy in this market, meaning the current sell-the-GLP-1 narrative could be premature if payers and physicians continue to accept nausea as the price of meaningful weight loss.

Key Decisions for Investors

• Trim exposure to the most crowded obesity leaders over the next 1-3 months; if you own high-multiple names like LLY or NVO, consider selling covered calls 10-15% OTM to monetize the increased headline risk while retaining core upside.
• Add to diversified large-cap biotech platforms with obesity adjacency and broader pipeline optionality over the next 6-12 months; a basket long XBI or a pair of long platform names vs short single-story obesity winners should benefit if sentiment shifts from molecule-specific to platform-specific value.
• Initiate a relative-value short in obesity pure-plays versus a basket of peptide/manufacturing enablers if the market starts pricing in non-GLP-1 displacement; use a 3-6 month horizon and size for binary preclinical translation risk.
• For event-driven accounts, buy cheap downside protection on obesity leaders into the next 1-2 catalysts; the catalyst path is news-flow driven rather than earnings-driven, so 1-2 quarter-dated puts can hedge a sudden multiple reset.
• Do not short the category outright: the base case remains durable demand growth. Instead, fade the highest expectations and look for dislocations between fundamental cash flow durability and narrative-driven multiple expansion.